Next Article in Journal
Protective Effects of Melatonin Against Aristolochic Acid-Induced Nephropathy in Mice
Previous Article in Journal
4-Aminobenzoic Acid Derivatives: Converting Folate Precursor to Antimicrobial and Cytotoxic Agents
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomolecules
Volume 10
Issue 1
10.3390/biom10010010
biomolecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Challenges Faced with Small Molecular Modulators of Potassium Current Channel Isoform Kv1.5

by
Zefeng Zhao
1,2,
Songsong Ruan
1,2,
Xiaoming Ma
1,2,
Qian Feng
1,2,
Zhuosong Xie
1,2,
Zhuang Nie
1,2,
Peinan Fan
1,2,
Mingcheng Qian
3,4,
Xirui He
5,
Shaoping Wu
1,2,*,
Yongmin Zhang
1,2,6 and
Xiaohui Zheng
1,2
1
Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, Northwest University, 229 Taibai Road, Xi’an 710069, China
2
Biomedicine Key Laboratory of Shaanxi Province, School of Pharmacy, Northwest University, 229 Taibai Road, Xi’an 710069, China
3
Department of Medicinal Chemistry, School of Pharmaceutical Engineering and Life Science, Changzhou University, Changzhou 213164, China
4
Laboratory for Medicinal Chemistry, Ghent University, Ottergemsesteenweg 460, B-9000 Ghent, Belgium
5
Department of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai 519041, China
6
Sorbonne Université, Institut Parisien de Chimie Moléculaire, CNRS UMR 8232, 4 place Jussieu, 75005 Paris, France
*
Author to whom correspondence should be addressed.
Biomolecules 2020, 10(1), 10; https://doi.org/10.3390/biom10010010
Submission received: 13 November 2019 / Revised: 8 December 2019 / Accepted: 10 December 2019 / Published: 19 December 2019
(This article belongs to the Section Chemical Biology)
Browse Figures
Versions Notes

Abstract

:
The voltage-gated potassium channel Kv1.5, which mediates the cardiac ultra-rapid delayed-rectifier (IKur) current in human cells, has a crucial role in atrial fibrillation. Therefore, the design of selective Kv1.5 modulators is essential for the treatment of pathophysiological conditions involving Kv1.5 activity. This review summarizes the progress of molecular structures and the functionality of different types of Kv1.5 modulators, with a focus on clinical cardiovascular drugs and a number of active natural products, through a summarization of 96 compounds currently widely used. Furthermore, we also discuss the contributions of Kv1.5 and the regulation of the structure-activity relationship (SAR) of synthetic Kv1.5 inhibitors in human pathophysiology. SAR analysis is regarded as a useful strategy in structural elucidation, as it relates to the characteristics that improve compounds targeting Kv1.5. Herein, we present previous studies regarding the structural, pharmacological, and SAR information of the Kv1.5 modulator, through which we can assist in identifying and designing potent and specific Kv1.5 inhibitors in the treatment of diseases involving Kv1.5 activity.

Graphical Abstract

1. Introduction

The voltage-gated potassium channel Kv1.5, which mediates the cardiac ultra-rapid delayed-rectifier (IKur) current in cells [1], is an attractive familial atrial fibrillation (AF) type 7 drug target, because it is selectively expressed in the atria but not in the ventricles of human cells [2]. AF is the most common cardiac arrhythmia facing physicians, afflicting 13% of men and 11% of women over 85 years of age. In atrial tissue from AF donors, the inhibition of IKur extends the repolarization phase of the atrial cardiac action potential, thereby providing desirable antiarrhythmic effects without the risk of drug-induced torsade de pointes. It is noteworthy that loss-of-function Kv1.5 mutations are associated with AF, and many companies are currently exploring IKur modulators for the treatment of AF [3].
The Kv1.5 protein is encoded by the KCNA5 gene with a length of 602 amino acids in mice (Unitprot Entry: Q61762) and rat (Unitprot Entry: P19024) sequences and 613 amino acids in the human sequence (Unitprot Entry: P22460). According to the Basic Local Alignment Search Tool (BLAST) result, the sequence of Kv1.5 is similar to homology targets Kv1.1, Kv1.2, and Kv1.3 in most regions, whereas differences mainly occur toward the start and end terminals of the sequence (see Figure 1C,D). The Kv1.5 channel belongs to the shaker-type voltage-gated K+ channel family, and it comprises four pore-forming α-subunits, each containing six transmembrane segments, named S1–S6 [4,5]. A pore region is formed between the pore helix and S6 domain of each subunit, which contains the selectivity filter through which K+ ions flow across the plasma membrane [6,7]. Currently, the structure of the Kv1.5 protein is still awaiting identification; however, alanine-scanning mutagenesis and homologous modeling studies provide us with some amino acids, including Thr479, Ile502, Val505, Ile508, and Val512, which reside within the deep pore (Thr479-Val481) and lower S6 (Cys500-Val512) regions as putative binding sites for open-channel blockers [8,9,10,11,12,13] (Figure 1B). This not only helps us to understand the drug targets more comprehensively, but also saves time with regard to the development of potential clinical candidates in the future. From this perspective, we highlight recent advances in the discovery of small molecules as modulators of Kv1.5, and we discuss the structure-activity relationship (SAR) studies of currently used synthetic Kv1.5 inhibitors.

2. Summarization of Models and Mechanisms of Kv1.5 Modulators

To date, various kinds of Kv1.5 modulators have been disclosed, herein, we summarize the molecular structures and functionality of different types of Kv1.5 modulators with their chemical structure as follows (Table 1, Figure 2). As shown in Table 1, the existing Kv1.5 modulators can be divided into four categories: clinical cardiovascular drugs (1–14), other clinical drugs (15–28), drugs in development (29–37), and natural products (38–56). With the development of pharmacology, more and more experiment models including rats, HEK cells, CHO cells, Xenopus laevis oocytes, and Ltk- cells have been used to evaluate the effect of Kv1.5 channel modulators; the parameters containing mRNA expression, IKur, effective refractory period (ERP), and action potential duration (APD) were utilized to reveal the improvement degree of AF. In principle, the Kv1.5 modulators can lengthen the time course of ERP and APD to protect heart from the harm of AF.
Although the structure of Kv1.5 protein has not been characterized yet, current researches provide information for the development of Kv1.5 inhibitors according to fragment-based drug design and structure-based drug design. In regard to the design of Kv1.5 inhibitor, for the instance of the typical candidate vernakalant, in the pharmacophore model, hydrogen bond receptor, hydrogen bond donor, and hydrophobic groups should be present in the structure (Figure 2A) to play a role in the transmembrane effect to interact with the Kv1.5 channel. From the potential binding domain of vernakalant in Kv1.5 [8,14] (Figure 2B), we can see that the positively charged moiety bound in the cationophilic inner pore (mainly formed by electron-donating residues including alanine, leucine, and valine) formed a cationic “blocking particle” causing a block of the potassium channel; additionally, the uncharged dimethoxyphenyl moiety of a vernakalant has a tendency to bind in hydrophobic subunit interfaces including residues Ile 502 and Val 505. Functionally important residue isoleucine I502 in the inner helix S6 is exposed into the subunit interface of the pore module rather than into the inner pore. It is worth noting that mutations of Ile 502 decrease the potency of vernakalant, flecainide, and AVE0118, which are the ligands with a long hydrophobic tail in the side chain of the structure.
It seems that the introduction of heterocyclic rings including pyrrole (vernakalant, bepridil, clemizole, and BMS-394136) and piperdine (lobeline, CD-160130, bupivacaine, paroxetine, and donepezil) is important because these moieties usually influence the acidification conditions of the molecules, in which a potentially protonated and thus positively charged drug may enter deeply into the channel pore in a voltage-dependent way [15].
As a result of the definite curative effects and pharmacokinetic parameters proved by clinical trials, conventional drugs in new use trends seem to be a feasible way to develop new therapy. Multiple cardiovascular drugs not designed for targeting Kv1.5 have shown Kv1.5 inhibitory effect including quinidine (9) and diltiazem (10), however, the selectivity of these compounds on Kv1.5 still needs to be investigated.
As for other clinical drugs, CNS agents include: donepezil (15), which is generally used as an anti-Alzheimer’s agent; paroxetine (16), fluoxetine (17), and sertraline (18), which are usually used as antidepressant agents; and bupivacaine (23), propofol (24), midazolam (25), tolbutamide (26), and benzocaine (27), which are utilized as anesthetic agents. hERGs (human ether-à-go-go-related genes) are widely associated with CNS diseases [16,17,18], thus it is not strange that active CNS agents can effectively modulate Kv1.5 according to the homology of the protein. Especially the neurotransmitter acetylcholine, which is an important substance that modulates the acetylcholine-activated K+ current [19], however, only the piperidine type acetylcholine inhibitor donepezil showed significant inhibitory effect on Kv1.5, the same phenomenon was not present in another inhibitor tacrine [15], suggesting the selectivity of the binding site of Kv1.5.
Generally, Kv1.5 drugs in development are not going smoothly. The projects listed in Table 1 have been discontinued till now. Effectiveness, toxicity, and druggability should be taken into account at this stage. Persistence of investigation in this field is necessary because the listed compound like AZD-7009 (30) can not only alleviate the suffering of patients from intermittent AF but also plays a role in relieving durative AF which continues to attack for more than 48 h [20]. The major voltage-gated K+ channels expressed in the vasculature are Kv1.2, Kv1.5, Kv2.1, and Kv7.4/7.5 [21]. Kv1.3, another Shaker-related family voltage-gated K+ channel, is closely related to the hERG channels regulated by Kv1.1 [22], which are the important targets influencing the prolongation of Q band to the end of T band (QT) syndrome and torsade pointes attributed to the gain-of-function mutations of clinical candidates whose details are being requested by drug regulatory authorities. Limitations in the ability of high-throughput screening methods to monitor the complex behavior of hERG have restricted the discovery of activators. It is noteworthy that some inhibitors of Kv1.5 channels listed in Table 1 are not specific voltage-gated K+ channels for Kv1.5, and some of which also block Kv1.3 channels (e.g., 4-aminopiridine (2), nifedipine (6), diltiazem (10), tetraethylammonium (11), propofol (24) [23], resveratrol (52) [24], and correolide (55)). Application of these drugs may result in side effects related to the inhibition of Kv1.3 channels like immune suppression, thus more attention should be paid to the toxicity to hERG-related targets of Kv1.5 developing candidates. Additionally, in the field of immunization [25], nuclear factor erythroid 2-related factor (Nrf2)-induced oxidative stress-inducible protein 1/p62 enhances the inhibition of pulmonary arterial Kv1.5 channels under acute hypoxia, and the 1/p62-Kv1.3-integrin axis provides novel insight into the molecular mechanisms underlying redox-regulated cell signaling in stress-induced biological responses, which broaden future potential directions.
A variety of natural products have been proven to modulate Kv1.5, but the exploration of novel skeleton could be helpful for the current dilemma. Among the isolated compounds, the main types are terpenoids (38–41), alakaloids (42–47), and flavonoids (48–50). Terpenoids are widely reported to inhibit potassium channels [26,27,28], however, the stability and difficulty in preparation because of the lack of a fluorescence group and the abundance in chiral carbon are worth worrying about in the development. Alkaloids, as well as polypeptides like kaliotoxin (54) and toxins from marine animals like tetrodotoxin, have been disclosed to inhibit ion channel activity, but the toxicity of these types of compounds is also concerning; after all, hERG toxicity has attracted the attention of the FDA and drugs like bepridil have been withdrawn because of their toxicity [29]. Bioactive flavonoids are also proven to modulate the Kv1.5 channel; among them is quercetin (50), a minor compound and activator of Kv1.5, with the tendency of developing flavonoids and phenols as health care products or food additives.This class of compounds may play a role in the daily prevention against Kv1.5 disease.

3. Synthetic Kv1.5 Inhibitors and SAR Investigations

In this section we collated information about chemical synthesis, pharmacological properties, and SAR investigations in the published literature from 2003 to 2019 and summarized them in a timeline. The previous work was briefly introduced in the description ofthe potential synthetic derivatives and chemical structure of compounds, and the SAR studies are listed in the corresponding figures in the perspective of medicinal chemistry. As we can see, multiple scaffolds include 5-methoxypsoralen (60,68), tetrahydroindolone (62–65), benzopyran sulfonamides (70–72), dihydropyrazolopyrimidine (73,81), and phenylquinazoline (90–92). Compounds (86–88) have been reported to be effective in inhibiting Kv1.5, suggesting potential future directions for investigations about Kv1.5 inhibitors. It is noteworthy that research from Bristol-Myers Squibb has contributed greatly with data about pharmacology and pharmacokinetics of active compounds in blocking Kv1.5, increasing the possibility that we can conquer the diseases targeting Kv1.5.
In 2003, Peukert and co-workers [80] synthesized a series of ortho-disubstituted bisaryl compounds as blockers of the Kv1.5 channel. Among the derivatives, the most potent compounds 57 (IC50: 0.7 μM) and 58 (IC50: 0.16 μM) inhibited the Kv1.5 channel with sub-micromolar half-blocking concentrations and displayed three fold selectivity over Kv1.3 and no significant effect on the hERG channel and sodium currents (Figure 3).
In 2004, Peukert et al. [81] synthesized several anthranilic amides as novel blockers of the Kv1.5 channel. The most hopeful analogue 59 showed moderate Kv1.5 inhibition (IC50: 0.7 μM) with good oral bioavailability, however, no significant effect on the IKr current of 59 was detected (Figure 4).
Inspired from the precursor 5-methoxypsoralen isolated from Rutagraveolens, Schmitz and colleagues [82] prepared a series of phenoxyalkoxypsoralen analogues and evaluated their voltage-gated ion channel blocker potency. The most potent and “druglike” compound of this series, 5-(4-phenoxybutoxy) psoralen (PAP-1, 60), blocks Kv1.3 in a use-dependent manner, with a Hill coefficient of 2 and an EC50 of 2 nM, by preferentially binding to the C-type inactivated state of the channel. PAP-1 is 23 fold selective over Kv1.5, 33–125 fold selective over other Kv1 family channels, and 500–7500 fold selective over Kv2.1, Kv3.1, Kv3.2, Kv4.2, hERG, calcium-activated K channels, Na, Ca, and Cl channels. PAP-1 does not exhibit cytotoxic or phototoxic effects, is negative in the Ames test, and affects cytochrome P450-dependent enzymes only at micromolar concentrations (Figure 5).
In 2006, Blass et al. [83] synthesized a cluster of (2-phenethyl-2H-1,2,3-triazol-4-yl) (phenyl) methanone and examined for utility as Kv1.5 channel blockers for the treatment of atrial fibrillation. The results showed that O substitution in the 4-position of the acetophenone-derived portion of the scaffold is highly favored, and the most active compound 61 blockaded Kv1.5 for 99% at a concentration of 1 μM (Figure 6).
Fluxe and co-workers [84] synthesized multiple tetrahydroindolone-derived carbamates as potent Kv1.5 blockers. The most promising analogues 62 and 63 exhibited the strongest Kv1.5 inhibitory effect with IC50 values of 67 and 21 nM, respectively. They were also very selective over hERG (> 450 fold) and L-type calcium channels (> 450 fold) (Figure 7).
Subsequently, Wu et al. [85] designed and synthesized tetrahydroindolone derived semicarbazones as selective Kv1.5 blockers. Compounds 64 and 65 showed good selectivity for the blockade of Kv1.5 (IC50: 0.13 μM for two compounds), moreover, in an anesthetized pig model, compounds 64 and 65 increased atrial ERP by about 28% and 18%, respectively, in the right atrium without affecting ventricular ERP (Figure 8).
Based on a diisopropyl amide scaffold, a series of potent Kv1.5 ion channel antagonists were synthesized by Nanda and colleagues [86]. The most active derivative 66, which was a single active enantiomer of the diastereomerically pure racemic analog, exhibited significant atrial-selective effects in an in vivo model (IC50: 150 nM) (Figure 9).
Trotter and co-workers [87] designed and synthesized a group of isoquinoline-3-nitriles as orally Kv1.5 antagonists for the treatment of AF. The ethanolamide derivative 67 exhibited improved potency (Kv1.5 HT-Clamp IC50: 60 nM), excellent selectivity versus hERG, and good pharmacokinetic properties. Rat EP experiments confirmed that the compound potently increased ARP without significant effects on AVRP− (Figure 10).
In 2007, Eun et al. [88] synthesized multiple psoralen derivatives as hKvl.5 channel blockers. Among them, compound 68 was the most potent in blocking hKv1.5 (IC50: 27.4 nM), much stronger than the lead compound psoralen. Compound 68 accelerated the inactivation kinetics of the hKvl.5 channel and slowed the deactivation kinetics of the hKv1.5 current resulting in a tail crossover phenomenon. Compound 68 inhibited the hKvl.5 current in a use-dependent manner (Figure 11).
Jackson and co-workers [89] prepared several classes of thiazolidine-based Kv1.5 blockers. The most promising analogue 69 derived from 3,4-dimethylacetophenone exhibited the strongest inhibitory effect with an IC50 value of 69 nM (Figure 12).
Lloyd et al. [90] synthesized a series of benzopyran sulfonamides and determined Kv1.5 potassium channel blocking effects. Among the productions, derivative 70 exhibited the most significant activity (IC50: 57 nM), and a moderate inhibition (35%) of hERG at a concentration of 10 μM (Figure 13).
In 2008, benzopyran sulfonamides derivatives were further investigated [91]. Compound 71 and 72 were considered as the most active derivatives in the two series of compounds with IC50 values of 46 and 378 nM in the inhibition of current in a L-929 cell model, respectively. Additionally, at the concentration of 1.0 μM, compound 72 displayed the most significant inbitory effect in the current of L-929 cells with an inhibitory ratio of 89% (Figure 14).
Vaccaro and co-workers [90] synthesized a series of dihydropyrazolopyrimidine analogues as Kv1.5 inhibitors. The most promising compound 73 showed the best potential in suppressing Kv1.5, with inhibitory effects on hERG (69%) and INa10 (42%) at a concentration of 10 μM (Figure 15).
In 2008, Gross and co-workers [92] synthesized aryl sulfonamido tetralin as a Kv1.5 inhibitor according to the basis of previous work. Among the productions, compound 74 exhibited remarkable Kv1.5 inhibitions with an IC50 value of 90 nM; in addition, moderate hERG inhibition was detected at the dose of 10 μM (39%), indicating the potential for further development of clinical candidates (Figure 16).
According to the structure of marketed drugs amiodarone and vernakalant, Blass et al. [93] synthesized a series of imidazolidinone derivatives as a potential treatment for atrial arrhythmia. KVI-020/WYE-160020 (75) exhibited the efficacy in clinically relevant models of AF and mechanistic models of the cardiac action potential with acceptable pharmacokinetic and pharmaceutical properties. The pharmacology IC50 values for compound 75 in Kv1.5, hERG, Nav1.5, Cav1.3, Cav1.2, Kv1.1, Kv1.3, and Kv4.3 were 0.48, 15.1, >30, 23.4, >30, 2.66, 1.41, and 3.87 μM in vitro, respectively (Figure 17).
In 2010, Lloyd and co-workers [58] developed a series of pyrazolodihydropyrimidines as potent and selective Kv1.5 blockers based on previous studies. The most promising analogue BMS-394136 (76) displayed excellent activity in blocking Kv1.5 (IC50: 50 nM) and very good selectivity over hERG, sodium, and L-type calcium ion channels with good pharmacokinetic parameters (Figure 18).
In 2012, Blass [94] prepared several heteroarylsulfonamides as Kv1.5 inhibitors. The active analogues 77, 78 and 79 exhibited 100% inhibition of Kv1.5 using stably transfected HEK293 cells and the FLIPR potassium ion channel assay, suggesting good potential for further investigation (Figure 19).
Finlay and colleagues [95] prepared several dihydropyrazolo[1,5-a]pyrimidine derivatives. Among the synthetic compounds, compound 80 showed potential to be a selective IKur inhibitor with Kv1.5 IC50 of 0.15 μM and hERG with an IC50 value >10 μM. Furthermore, favorable pharmacokinetic properties in rats and dogs of 80 were determined; compound 80 was identified with less than 1% GSH adducts formation with an improved PK profile and equivalent PD efficacy to the lead compound (Figure 20).
In 2013, triazolo and imidazo were introduced into the active scaffold dihydropyrazolopyrimidine [96]. Trifluoromethylcyclohexyl triazole analogue 81 was identified as a potent and selective Kv1.5 inhibitor (IC50: 133 nM) with an acceptable PK and liability profile. Compound 81 demonstrated an improved rat PK profile and was advanced to the rat PD model (Figure 21).
With the help of a pharmacophore model, Guo et al. [97] designed and synthesized a series of indole derivatives as potent Kv1.5 inhibitors. The most promising compound 82 displayed significant INa, HEK 293 hKv1.5, and CHO hERG inhibitory activities with IC50 values of 52.6, 0.51, and 418.35 μM, respectively, which displayed remarkable selectivity and ameliorating effects on atrial effective refractory period (AERP) and VERP (Figure 22).
Olsson and co-workers [98] possessed design and pharmacological evaluation of multiple potential hits targeting on Kv1.5. The compound 83 performed the best in vitro activity with Kv1.5 IC50 of 0.08 μM in diphenylphosphinic amide and diphenylphosphine oxide analogues (Figure 23). However, both hERG and IKs active and remarkable safety in rats of compound 83 was detected and judged unsuitable for in vivo testing; conversely, the derivative 84 was regarded as a hopeful compound for further development with Kv1.5 IC50, IKs, Ceu20, and QTmax change values for 1.0 μM, >33%, 0.6 μM, and <10%, respectively.
In 2014, the subsequent study was updated [99], and a series of lactam sulfonamide derivatives was prepared and the Kv1.5 inhibitory potency was evaluated. The most promising candidate 85 inhibited Kv1.5 with an IC50 value of 0.21 μM and caused a marked increase in the atrium ERP with a Ceu20 of 0.35 μM, which was at the same order of magnitude as the IC50 value from the human cellular assay. The human hERG channel was blocked by compound 85 with an IC50 value of 30 μM, indicating a 140 fold margin of the hERG and Kv1.5 in vitro values. No measurable change was noted in the QT-interval in the rabbit experiments, which also indicated a good margin to block of the hERG channel. The compound 85 was well tolerated in rabbits with no signs of the CNS-like side effects observed for other Kv1.5 blockers (Figure 24).
Johnson et al. [100] synthesized phenethylaminoheterocycles and assayed for inhibition of the Kv1.5 potassium ion channel as a potential approach to the treatment of atrial fibrillation. Combination of the indazole with a cyclohexane-based template gave the most promising derivative 86 (Kv1.5 IC50: 138 nM) which demonstrated significant prolongation of AERP in the rabbit pharmacodynamic model (Figure 25).
Guo and colleagues [101] prepared a series of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors. The most potent compound 87 exerted significant activity on hKv1.5 (IC50: 0.72 μM), balanced Log D, and permeability. In addition, comparable in vivo potency with sotalol and dronedarone and remarkable safety in rats of compound 87 were detected as well (Figure 26).
In 2016, Kajanus et al. [102] synthesized multiple isoindolinone compounds as Kv1.5 blockers. The most potent compounds 88 and 89 exhibited an inhibitory effect with the IC50 values of 0.4 and 0.7 µM on Kv1.5, respectively. The above-mentioned two compounds were found to have desirable in vivo PK properties in a mouse model (Figure 27).
Finlay and co-workers [103] explored phenylquinazoline derivatives as Kv1.5 inhibitors. 5-Phenyl-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine (90) was identified as a potent and ion channel selective inhibitor (Kv1.5 IC50: 90 nM, hERG inhibition: 43% at 10 μM) with robust efficacy in the pre-clinical rat ventricular effective refractory period (VERP) model and the rabbit atrial effective refractory period (AERP) model (Figure 28).
Subsequently in 2017, Gunaga et al. [58] modified the structure of 91 with a series of analogues and evaluated the IKur inhibitory effect. 5-[5-Phenyl-4-(pyridin-2-ylmethylamino)-quinazolin-2-yl] pyridine-3-sulfonamide (92) was identified as the lead compound in this series with good selectivity over hERG (Kv1.5 IC50: 50 nM, hERG IC50: 1.9 μM). Compound 91 exhibited robust effects in rabbit and canine pharmacodynamic models and an acceptable cross-species pharmacokinetic profile which was then advanced as a clinical candidate. Further optimization of 91 to mitigate pH-dependent absorption resulted in identification of the corresponding phosphoramide prodrug (92) with an improved solubility and pharmacokinetic profile (Figure 29).
According to the skeleton of Agelas alkaloids clathrodin, oroidin, and hymenidin, Zidar and colleagues [104] synthesized multiple derivatives as inhibitors of the voltage-gated potassium channels. The most potent inhibitor was (E)-N-(3-(2-amino-1H-imidazol-4-yl)allyl)-4,5-dichloro-1H-pyrrole-2-carboxamide (93) with IC50 values between 1.4 and 6.1 mM against Kv1.3, Kv1.4, Kv1.5, and Kv1.6 channels (Kv1.5 IC50: 6.1 μM) (Figure 30).
Wolkenberg et al. [105] told the story of the development of prospective candidate MK-1832 (94) (Figure 31). Based on the structure of MK-0448, a cluster of derivatives were synthesized and tested the Kv1.5 inhibitory effect and in vivo and in vitro toxicity. MK-1832 (94) was considered to be the best derivative with pharmacological parameters including Kv1.5, Ikur, and Ikr(hERG) IC50 values for 29, 11 and 1.28 × 10 5 nM, respectively, and pharmacokinetic parameters including dog in vivo atrial refractory period EC10 for 14 nM and threshold change in ventricular refractory period >25 μM.
In 2019, Kajanus and colleagues [106] prepared potassium channel blocking 1,2-bis(aryl)ethane-1,2-diamines active as antiarrhythmic agents. The most promising analogue 95 displayed significant nanomolar potency in blocking Kv1.5 in human atrial myocytes (IC50: 1.7 μM, IKur IC50: 60 nM) and based on the PD data, the estimated dose for men was 700 mg/day (Figure 32).
Recently, natural products with novel structural motif as a Kv1.5 inhibitor also gained progress in this field. In the sequence of the isolation of compound debromoaplysiatoxin A (38) and debromoaplysiatoxin B (39) [63], Tang and co-workers [14] identified other novel aplysiatoxin derivatives from the marine cyanobacterium Lyngbya sp. Among them, compound oscillatoxin E (96) with the hexane-tetrahydropyran of a spirobicyclic system skeleton exhibited the strongest Kv1.5 inhibition (IC50: 0.79 μM) in the CHO cells at an HP of -80 mV (Figure 33).

4. Conclusions

Herein the target and the pharmacological properties with structural, pharmacological, and SAR information of Kv1.5 modulators were discussed. Detailed descriptions of pharmacology parameters and SAR studies provide an actionable path forward for medicinal chemists to optimize the structure of Kv1.5 modulators. Further experiments should improve the PK and safety after the effectiveness is proven. Design and development of potential and selective Kv1.5 modulators are important and challenging tasks. Based on the existing pharmacophoric requirements and potential protein structure parsed in the future, some novel effective Kv1.5 modulators may be designed and prepared [107,108]. However, gaps exist in the scientific studies on Kv1.5 modulators. Firstly, the selectivity of existing Kv1.5 modulators remains to be investigated, and more specific modulators aiming at the Kv1.5 channel are needed in the future. Secondly, from the point of application, the market of AF is relatively small, and the sales condition of marked anti-AF agents is not satisfactory as a whole, thus more in-depth pharmacological investigation of roles of Kv1.5 are required in the future. Moreover, the definite structure of Kv1.5 protein is still vacant, difficulties and potential fallacy are still consistent in the design of modulators only estimating by the pocket of homologous models.
SAR investigation is crucial for the development of novel promising clinical candidates. It is anticipated that the information compiled in this review article not only updates researchers with the recently reported pharmacology and SAR of Kv1.5 modulators, but also motivates them to design and synthesize promising Kv1.5 modulators with improved medicinal properties.

Funding

This work was supported by the Changjiang Scholars and Innovative Research Team in Universities, Ministry of Education of China (IRT_15R55), the 9th Group of Hundred Talent Program of Shaanxi Province (2017), Biomedicine Key Laboratory of Shaanxi Province (No. 2018SZS41), and the International Science and Technology Cooperation Program of Shaanxi Province (No. 2019KWZ-001).

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

AFAtrial fibrillation
BLASTBasic Local Alignment Search Tool
Ceu20Unbound steady-state plasma concentration
CHO cellsChinese hamster ovary cells
CNSCentral nervous system
EDGsElectron donating groups
EWGsElectron withdrawing groups
HEK cellsHuman embryonic kidney 293 cells
hERGHuman ether-à-go-go-related gene
hKv1.5 channelsHuman Kv1.5 channels
Human PASMCsHuman pulmonary arterial smooth muscle cells
IKurCardiac ultra-rapid delayed-rectifier
IC5050% inhibitory concentration
IleIsoleucine
Nrf2Nuclear factor erythroid 2-related factor
SARStructure–activity relationship
ThrThreonine
ValValine
VERPVentricular effective refractory period

References

  1. Milnes, J.T.; Madge, D.J.; Ford, J.W. New pharmacological approaches to atrial fibrillation. Drug Discov. Today 2012, 17, 654–659. [Google Scholar] [CrossRef] [PubMed]
  2. Amos, G.J.; Wettwer, E.; Metzger, F.; Li, Q.; Himmel, H.M.; Ravens, U. Differences between outward currents of human atrial, and subepicardial ventricular myocytes. J. Physiol. 1996, 491, 31–50. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Humphries, E.S.A.; Dart, C. Neuronal and cardiovascular potassium channels as therapeutic drug targets: Promise and pitfalls. J. Biomol. Screen. 2015, 20, 1055–1073. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Kojima, A.; Ito, Y.; Ding, W.-G.; Kitagawa, H.; Matsuura, H. Interaction of propofol with voltage-gated human Kv1.5 channel through specific amino acids within the pore region. Eur. J. Pharmacol. 2015, 764, 622–632. [Google Scholar] [CrossRef] [PubMed]
  5. Nerbonne, J.M.; Kass, R.S. Molecular physiology of cardiac repolarization. Physiol. Rev. 2005, 85, 1205–1253. [Google Scholar] [CrossRef] [Green Version]
  6. Tamargo, J.; Caballero, R.; Gomez, R.; Delpon, E. I-Kur/Kv1.5 channel blockers for the treatment of atrial fibrillation. Expert Opin. Inv. Drug. 2009, 18, 399–416. [Google Scholar] [CrossRef]
  7. Yellen, G. The voltage-gated potassium channels and their relatives. Nature 2002, 419, 35–42. [Google Scholar] [CrossRef]
  8. Tikhonov, D.B.; Zhorov, B.S. Homology modeling of Kv1.5 channel block by cationic and electroneutral ligands. Biochim. Biophys. Acta. 2014, 1838, 978–987. [Google Scholar] [CrossRef] [Green Version]
  9. Wu, J.; Ding, W.G.; Matsuura, H.; Tsuji, K.; Zang, W.J.; Horie, M. Inhibitory actions of the phosphatidylinositol 3-kinase inhibitor LY294002 on the human Kv1.5 channel. Brit. J. Pharmacol. 2009, 156, 377–387. [Google Scholar] [CrossRef] [Green Version]
  10. Guex, N.; Peitsch, M.C.; Schwede, T. Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: A historical perspective. Electrophoresis 2009, 30, S162–S173. [Google Scholar] [CrossRef]
  11. Chen, R.; Chung, S.-H. Inhibition of Voltage-Gated K+ Channel Kv1.5 by Antiarrhythmic Drugs. Biochemistry 2018, 57, 2704–2710. [Google Scholar] [CrossRef] [PubMed]
  12. Altschul, S.F.; Madden, T.L.; Schaffer, A.A.; Zhang, J.; Zhang, Z.; Miller, W.; Lipman, D.J. Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucleic Acids Res. 1997, 25, 3389–3402. [Google Scholar] [CrossRef] [Green Version]
  13. Robert, X.; Gouet, P. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res. 2014, 42, W320–W324. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Tang, Y.H.; Wu, J.; Fan, T.T.; Zhang, H.H.; Gong, X.X.; Cao, Z.Y.; Zhang, J.; Lin, H.W.; Han, B.N. Chemical and biological study of aplysiatoxin derivatives showing inhibition of potassium channel Kv1.5. RSC Adv. 2019, 9, 7594–7600. [Google Scholar] [CrossRef] [Green Version]
  15. Li, K.; Cheng, N.; Li, X.T. Inhibitory effects of cholinesterase inhibitor donepezil on the Kv1.5 potassium channel. Sci. Rep. 2017, 7, 41509–41518. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Chen, X.; Xue, B.; Wang, J.; Liu, H.; Shi, L.; Xie, J. Potassium channels: A potential therapeutic target for Parkinson’s disease. Neurosci. Bull. 2018, 34, 341–348. [Google Scholar] [CrossRef] [PubMed]
  17. Li, P.; Chen, Z.; Xu, H.; Sun, H.; Li, H.; Liu, H.; Yang, H.; Gao, Z.; Jiang, H.; Li, M. The gating charge pathway of an epilepsy-associated potassium channel accommodates chemical ligands. Cell Res. 2013, 23, 1106–1118. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  18. Seifert, G.; Henneberger, C.; Steinhaeuser, C. Diversity of astrocyte potassium channels: An update. Brain Res. Bull. 2018, 136, 26–36. [Google Scholar] [CrossRef]
  19. Schmitt, N.; Grunnet, M.; Olesen, S.P. Cardiac potassium channel subtypes: New roles in repolarization and arrhythmia. Physiol. Rev. 2014, 94, 609–653. [Google Scholar] [CrossRef] [Green Version]
  20. Geller, J.C.; Egstrup, K.; Kulakowski, P.; Rosenqvist, M.; Jansson, M.A.; Berggren, A.; Edvardsson, N.; Sager, P.; Crijns, H.J. Rapid conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. J. Clin. Pharmacol. 2009, 49, 312–322. [Google Scholar] [CrossRef]
  21. Ng, F.L.; Davis, A.J.; Jepps, T.A.; Harhun, M.I.; Yeung, S.Y.; Wan, A.; Reddy, M.; Melville, D.; Nardi, A.; Khong, T.K.; et al. Expression and function of the K plus channel KCNQ genes in human arteries. Br. J. Pharmacol. 2011, 162, 42–53. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Barros, F.; Pardo, L.A.; Dominguez, P.; Maria Sierra, L.; De la Pena, P. New Structures and Gating of Voltage-Dependent Potassium (Kv) Channels and Their Relatives: A Multi-Domain and Dynamic Question. Int. J. Mol. Sci. 2019, 20, 248. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Mozrzymas, J.W.; Teisseyre, A.; Vittur, F. Propofol blocks voltage-gated potassium channels in human T lymphocytes. Biochem. Pharmacol. 1996, 52, 843–849. [Google Scholar] [CrossRef]
  24. Teisseyre, A.; Michalak, K. Inhibition of the activity of human lymphocyte Kv1.3 potassium channels by resveratrol. J. Membr. Biol. 2006, 214, 123–129. [Google Scholar] [CrossRef]
  25. Ishii, T.; Warabi, E.; Siow, R.C.M.; Mann, G.E. Sequestosome1/p62: A regulator of redox-sensitive voltage-activated potassium channels, arterial remodeling, inflammation, and neurite outgrowth. Free Radic. Biol. Med. 2013, 65, 102–116. [Google Scholar] [CrossRef]
  26. Dos Santos-Nascimento, T.; Veras, K.M.; Cruz, J.S.; Leal-Cardoso, J.H. Inhibitory Effect of Terpinen-4-ol on Voltage-Dependent Potassium Currents in Rat Small Sensory Neurons. J. Nat. Prod. 2015, 78, 173–180. [Google Scholar] [CrossRef]
  27. Kulcitki, V.; Harghel, P.; Ungur, N. Unusual cyclic terpenoids with terminal pendant prenyl moieties: From occurrence to synthesis. Nat. Prod. Rep. 2014, 31, 1686–1720. [Google Scholar] [CrossRef]
  28. Menezes, P.M.N.; Brito, M.C.; de Paiva, G.O.; dos Santos, C.O.; de Oliveira, L.M.; Ribeiro, L.A.D.; De Lima, J.T.; Lucchese, A.M.; Silva, F.S. Relaxant effect of Lippia origanoides essential oil in guinea-pig trachea smooth muscle involves potassium channels and soluble guanylyl cyclase. J. Ethnopharmacol. 2018, 220, 16–25. [Google Scholar] [CrossRef]
  29. Kalyaanamoorthy, S.; Barakat, K.H. Development of safe crugs: The hERG challenge. Med. Res. Rev. 2018, 38, 525–555. [Google Scholar] [CrossRef]
  30. Cheong, A.; Dedman, A.M.; Beech, D.J. Expression and function of native potassium channel (K-v alpha 1) subunits in terminal arterioles of rabbit. J. Physiol. 2001, 534, 691–700. [Google Scholar] [CrossRef]
  31. Xie, Y.; Ding, W.; Liu, Y.; Yu, M.; Sun, X.; Matsuura, H. Long-term 4-AP treatment facilitates functional expression of human Kv1.5 channel. Eur. J. Pharmacol. 2019, 844, 195–203. [Google Scholar] [CrossRef] [PubMed]
  32. Eldstrom, J.; Wang, Z.; Xu, H.; Pourrier, M.; Ezrin, A.; Gibson, K.; Fedida, D. The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels. Mol. Pharmacol. 2007, 72, 1522–1534. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Kodama, I.; Kamiya, K.; Honjo, H.; Toyama, J. Acute and chronic effects of amiodarone on mammalian ventricular cells. Jpn. Heart J. 1996, 37, 719–730. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Herrera, D.; Mamarbachi, A.; Simoes, M.; Parent, L.; Sauve, R.; Wang, Z.G.; Nattel, S. A single residue in the S6 transmembrane domain governs the differential flecainide sensitivity of voltage-gated potassium channels. Mol. Pharmacol. 2005, 68, 305–316. [Google Scholar] [CrossRef] [Green Version]
  35. Lin, S.; Wang, Z.; Fedida, D. Influence of permeating ions on Kv1.5 channel block by nifedipine. Am. J. Physiol. Heart Circ. Physiol. 2001, 280, H1160–H1172. [Google Scholar] [CrossRef]
  36. Franqueza, L.; Valenzuela, C.; Delpon, E.; Longobardo, M.; Caballero, R.; Tamargo, J. Effects of propafenone and 5-hydroxy-propafenone on hKv1.5 channels. Brit. J. Pharmacol. 1998, 125, 969–978. [Google Scholar] [CrossRef] [Green Version]
  37. Fedida, D. Gating charge and ionic currents associated with quinidine block of human Kv1.5 delayed rectifier channels. J. Physiol. 1997, 499, 661–675. [Google Scholar] [CrossRef] [Green Version]
  38. Caballero, R.; Gomez, R.; Nunez, L.; Moreno, I.; Tamargo, J.; Delpon, E. Diltiazem inhibits hKv1.5 and Kv4.3 currents at therapeutic concentrations. Cardiovasc. Res. 2004, 64, 457–466. [Google Scholar] [CrossRef]
  39. Chow, L.W.C.; Cheng, K.-S.; Wong, K.-L.; Leung, Y.-M. Voltage-gated K+ channels promote BT-474 breast cancer cell migration. Chin. J. Cancer Res. 2018, 30, 613–622. [Google Scholar] [CrossRef]
  40. Malayev, A.A.; Nelson, D.J.; Philipson, L.H. Mechanism of clofilium block of the human Kv1.5 delayed rectifier potassium channel. Mol. Pharmacol. 1995, 47, 198–205. [Google Scholar]
  41. Yang, I.C.H.; Scherz, M.W.; Bahinski, A.; Bennett, P.B.; Murray, K.T. Stereoselective interactions of the enantiomers of chromanol 293B with human voltage-gated potassium channels. J. Pharmacol. Exp. 2000, 294, 955–962. [Google Scholar]
  42. Kobayashi, S.; Reien, Y.; Ogura, T.; Saito, T.; Masuda, Y.; Nakaya, H. Inhibitory effect of bepridil on hKv1.5 channel current: Comparison with amiodarone and E-4031. Eur. J. Pharmacol. 2001, 430, 149–157. [Google Scholar] [CrossRef] [Green Version]
  43. Lee, H.M.; Hahn, S.J.; Choi, B.H. Blockade of Kv1.5 by paroxetine, an antidepressant drug. Korean J. Physiol. Pharmacol. 2016, 20, 75–82. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Dai, F.F.; Mao, Z.F.; Xia, J.; Zhu, S.P.; Wu, Z.Y. Fluoxetine protects against big endothelin-1 induced anti-apoptosis by rescuing Kv1.5 channels in human pulmonary arterial smooth muscle cells. Yonsei Med. J. 2012, 53, 842–848. [Google Scholar] [CrossRef] [PubMed]
  45. Lee, H.M.; Hahn, S.J.; Choi, B.H. Blockade of Kv1.5 channels by the antidepressant drug sertraline. Korean J. Physiol. Pharmacol. 2016, 20, 193–200. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Yu, J.; Park, M.-H.; Jo, S.-H. Inhibitory effects of cortisone and hydrocortisone on human Kv1.5 channel currents. Eur. J. Pharmacol. 2015, 746, 158–166. [Google Scholar] [CrossRef]
  47. Lammers, C.; Dartsch, T.; Brandt, M.C.; Rottlander, D.; Halbach, M.; Peinkofer, G.; Ockenpoehler, S.; Weiergraeber, M.; Schneider, T.; Reuter, H.; et al. Spironolactone prevents aldosterone induced increased duration of atrial fibrillation in rat. Cell Physiol. Biochem. 2012, 29, 833–840. [Google Scholar] [CrossRef]
  48. Frolov, R.V.; Singh, S. Celecoxib and ion channels: A story of unexpected discoveries. Eur. J. Pharmacol. 2014, 730, 61–71. [Google Scholar] [CrossRef]
  49. Luzhkov, V.B.; Nilsson, J.; Arhem, P.; Aqvist, J. Computational modelling of the open-state K(v)1.5 ion channel block by bupivacaine. Biochim. Biophys. Acta. 2003, 1652, 35–51. [Google Scholar] [CrossRef]
  50. Valenzuela, C.; Delpon, E.; Tamkun, M.M.; Tamargo, J.; Snyders, D.J. Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers. Biophys. J. 1995, 69, 418–427. [Google Scholar] [CrossRef] [Green Version]
  51. Vonderlin, N.; Fischer, F.; Zitron, E.; Seyler, C.; Scherer, D.; Thomas, D.; Katus, H.A.; Scholz, E.P. Inhibition of cardiac Kv1.5 potassium current by the anesthetic midazolam: Mode of action. Drug Des. Dev. 2014, 8, 2263–2271. [Google Scholar]
  52. Su, J.P.; Huang, Y.; Lenka, N.; Hescheler, J.; Ullrich, S. The expression and regulation of depolarization-activated K+ channels in the insulin-secreting cell line INS-1. Pflugers Arch. 2001, 442, 49–56. [Google Scholar] [CrossRef] [PubMed]
  53. Caballero, R.; Moreno, I.; Gonzalez, T.; Valenzuela, C.; Tamargo, J.; Delpon, E. Putative binding sites for benzocaine on a human cardiac cloned channel (Kv1.5). Cardiovasc. Res. 2002, 56, 104–117. [Google Scholar] [CrossRef] [Green Version]
  54. Jie, L.; Wu, W.; Li, G.; Xiao, G.; Zhang, S.; Li, G.; Wang, Y. Clemizole hydrochloride blocks cardiac potassium currents stably expressed in HEK 293 cells. Brit. J. Pharmacol. 2017, 174, 254–266. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Wirth, K.J.; Brendel, J.; Steinmeyer, K.; Linz, D.K.; Ruetten, H.; Goegelein, H. In vitro and in vivo effects of the atrial selective antiarrhythmic compound AVE1231. J. Cardiovasc. Pharmacol. 2007, 49, 197–206. [Google Scholar] [CrossRef]
  56. Persson, F.; Carlsson, L.; Duke, G.; Jacobson, I. Blocking characteristics of hKv1.5 and hKv4.3/hKChIP2.2 after administration of the novel antiarrhythmic compound AZD7009. J. Cardiovasc. Pharmacol. 2005, 46, 7–17. [Google Scholar] [CrossRef]
  57. Lloyd, J.; Finlay, H.J.; Vacarro, W.; Hyunh, T.; Kover, A.; Bhandaru, R.; Yan, L.; Atwal, K.; Conder, M.L.; Jenkins-West, T.; et al. Pyrrolidine amides of pyrazolodihydropyrimidines as potent and selective KV1.5 blockers. Bioorg. Med. Chem. Lett. 2010, 20, 1436–1439. [Google Scholar] [CrossRef]
  58. Gunaga, P.; Lloyd, J.; Mummadi, S.; Banerjee, A.; Dhondi, N.K.; Hennan, J.; Subray, V.; Jayaram, R.; Rajugowda, N.; Reddy, K.U.; et al. Selective I-Kur inhibitors for the potential treatment of atrial fibrillation: Optimization of the phenyl quinazoline series leading to clinical candidate 5- 5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl pyridine-3-sulfon amide. J. Med. Chem. 2017, 60, 3795–3803. [Google Scholar] [CrossRef]
  59. Loose, S.; Mueller, J.; Wettwer, E.; Knaut, M.; Ford, J.; Milnes, J.; Ravens, U. Effects of IKur blocker MK-0448 on human right atrial action potentials from patients in sinus rhythm and in permanent atrial fibrillation. Front. Pharmacol. 2014, 5, 26–32. [Google Scholar] [CrossRef] [Green Version]
  60. Ford, J.; Milnes, J.; El Haou, S.; Wettwer, E.; Loose, S.; Matschke, K.; Tyl, B.; Round, P.; Ravens, U. The positive frequency-dependent electrophysiological effects of the IKur inhibitor XEN-D0103 are desirable for the treatment of atrial fibrillation. Heart Rhythm 2016, 13, 555–564. [Google Scholar] [CrossRef] [Green Version]
  61. Gautier, P.; Guillemare, E.; Djandjighian, L.; Marion, A.; Planchenault, J.; Bernhart, C.; Herbert, J.M.; Nisato, D. In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C-Electrophysiological, anti-adrenergic, and anti-angiotensin II effects. J. Cardiovasc. Pharmacol. 2004, 44, 244–257. [Google Scholar] [CrossRef] [PubMed]
  62. Gasparoli, L.; D’Amico, M.; Masselli, M.; Pillozzi, S.; Caves, R.; Khuwaileh, R.; Tiedke, W.; Mugridge, K.; Pratesi, A.; Mitcheson, J.S.; et al. New pyrimido-indole compound CD-160130 preferentially inhibits the K(V)11.1B isoform and produces antileukemic effects without cardiotoxicity. Mol. Pharmacol. 2015, 87, 183–196. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Han, B.; Liang, T.; Keen, L.J.; Fan, T.; Zhang, X.; Xu, L.; Zhao, Q.; Wang, S.; Lin, H. Two marine cyanobacterial aplysiatoxin polyketides, neo-debromoaplysiatoxin A and B, with K+ channel inhibition activity. Org. Lett. 2018, 20, 578–581. [Google Scholar] [CrossRef] [PubMed]
  64. Grissmer, S.; Nguyen, A.N.; Aiyar, J.; Hanson, D.C.; Mather, R.J.; Gutman, G.A.; Karmilowicz, M.J.; Auperin, D.D.; Chandy, K.G. Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol. Pharmacol. 1994, 45, 1227–1234. [Google Scholar] [PubMed]
  65. Kwak, Y.G.; Kim, D.K.; Ma, T.; Park, S.-A.; Park, H.; Jung, Y.H.; Yoo, D.-J.; Eun, J.S. Torilin from Torilis japonica (Houtt.) DC. blocks hKv1.5 channel current. Arch. Pharmacol. Res. 2006, 29, 834–839. [Google Scholar] [CrossRef]
  66. Jin, S.; Guo, Q.; Xu, J.; Yu, P.; Liu, J.; Tang, Y. Antiarrhythmic ionic mechanism of Guanfu base A -Selective inhibition of late sodium current in isolated ventricular myocytes from guinea pigs. Chin. J. Nat. Med. 2015, 13, 361–367. [Google Scholar] [CrossRef]
  67. Jeong, I.; Choi, B.H.; Hahn, S.J. Effects of lobeline, a nicotinic receptor ligand, on the cloned Kv1.5. Pflugers Arch. 2010, 460, 851–862. [Google Scholar] [CrossRef]
  68. Fischer, F.; Vonderlin, N.; Zitron, E.; Seyler, C.; Scherer, D.; Becker, R.; Katus, H.A.; Scholz, E.P. Inhibition of cardiac Kv1.5 and Kv4.3 potassium channels by the class Ia anti-arrhythmic ajmaline: Mode of action. Naunyn Schmiedebergs Arch. Pharmacol. 2013, 386, 991–999. [Google Scholar]
  69. Choe, H.; Lee, Y.K.; Lee, Y.T.; Choe, H.; Ko, S.H.; Joo, C.U.; Kim, M.H.; Kim, G.S.; Eun, J.S.; Kim, J.H.; et al. Papaverine blocks hKv1.5 channel current and human atrial ultrarapid delayed rectifier K+ currents. Can. J. Cardiol. 2003, 304, 706–712. [Google Scholar] [CrossRef] [Green Version]
  70. Li, K.; Pi, M.; Li, X. The inhibitory effects of levo-tetrahydropalmatine on rat Kv1.5 channels expressed in HEK293 cells. Eur. J. Pharmacol. 2017, 809, 105–110. [Google Scholar] [CrossRef]
  71. Li, Y.F.; Tu, D.N.; Xiao, H.; Du, Y.M.; Zou, A.R.; Liao, Y.H.; Dong, S.H. Aconitine blocks HERG and Kv1.5 potassium channels. J. Ethnopharmacol. 2010, 131, 187–195. [Google Scholar] [CrossRef] [PubMed]
  72. Ou, X.; Bin, X.; Wang, L.; Li, M.; Yang, Y.; Fan, X.; Zeng, X. Myricetin inhibits K (v) 1.5 channels in HEK293 cells. Mol. Med. Rep. 2016, 13, 1725–1731. [Google Scholar] [CrossRef] [Green Version]
  73. Liu, Y.; Xu, X.; Liu, Z.; Du, X.; Chen, K.; Xin, X.; Jin, Z.; Shen, J.; Hu, Y.; Li, G.; et al. Effects of the natural flavone trimethylapigenin on cardiac potassium currents. Biochem. Pharmacol. 2012, 84, 498–506. [Google Scholar] [CrossRef] [PubMed]
  74. Yang, L.; Ma, J.; Zhang, P.; Zou, A.; Tu, D. Quercetin activates human Kv1.5 channels by a residue I502 in the S6 segment. Clin. Exp. Pharmacol. Physiol. 2009, 36, 154–161. [Google Scholar] [CrossRef] [PubMed]
  75. Wu, H.-J.; Wu, W.; Sun, H.-Y.; Qin, G.-W.; Wang, H.-B.; Wang, P.; Yalamanchili, H.K.; Wang, J.; Tse, H.-F.; Lau, C.-P.; et al. Acacetin causes a frequency- and use-dependent blockade of hKv1.5 channels by binding to the S6 domain. J. Mol. Cell. Cardiol. 2011, 51, 966–973. [Google Scholar] [CrossRef] [PubMed]
  76. Paffett, M.L.; Lucas, S.N.; Campen, M.J. Resveratrol reverses monocrotaline-induced pulmonary vascular and cardiac dysfunction: A potential role for atrogin-1 in smooth muscle. Vasc. Pharmacol. 2012, 56, 64–73. [Google Scholar] [CrossRef] [Green Version]
  77. Kwak, Y.G.; Choi, B.-H.; Kim, D.K.; Eun, J.S. Decursin from Angelica gigas Nakai blocks hKv1.5 channel. Biomol. Ther. 2011, 19, 33–37. [Google Scholar] [CrossRef] [Green Version]
  78. Karczewski, J.; Kiss, L.; Kane, S.A.; Koblan, K.S.; Lynch, R.J.; Spencer, R.H. High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5. Biochem. Pharmacol. 2009, 77, 177–185. [Google Scholar] [CrossRef]
  79. Yang, Q.; Lv, Q.; Feng, M.; Liu, M.; Feng, Y.; Lin, S.; Yang, J.; Hu, J. Taurine prevents the electrical remodeling in ach-CaCl2 induced atrial fibrillation in rats. In Taurine 10; Lee, D.H., Schaffer, S.W., Park, W., Kim, H.W., Eds.; Springer: Dordrecht, The Netherlands, 2017; Volume 975, pp. 821–830. [Google Scholar]
  80. Peukert, S.; Brendel, J.; Pirard, B.; Bruggemann, A.; Below, P.; Kleemann, H.W.; Hemmerle, H.; Schmidt, W. Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5. J. Med. Chem. 2003, 46, 486–498. [Google Scholar] [CrossRef]
  81. Peukert, S.; Brendel, J.; Pirard, B.; Strubing, C.; Kleemann, H.W.; Bohme, T.; Hemmerle, H. Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel. Bioorg. Med. Chem. Lett. 2004, 14, 2823–2827. [Google Scholar] [CrossRef]
  82. Schmitz, A.; Sankaranarayanan, A.; Azam, P.; Schmidt-Lassen, K.; Homerick, D.; Hansel, W.; Wulff, H. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol. Pharmacol. 2005, 68, 1254–1270. [Google Scholar] [CrossRef] [Green Version]
  83. Blass, B.E.; Coburn, K.; Lee, W.; Fairweather, N.; Fluxe, A.; Wu, S.; Janusz, J.M.; Murawsky, M.; Fadayel, G.M.; Fang, B.; et al. Synthesis and evaluation of (2-phenethyl-2H-1,2,3-triazol-4-yl)(phenyl) methanones as Kv1.5 channel blockers for the treatment of atrial fibrillation. Bioorg. Med. Chem. Lett. 2006, 16, 4629–4632. [Google Scholar] [CrossRef] [PubMed]
  84. Fluxe, A.; Wu, S.D.; Sheffer, J.B.; Janusz, J.M.; Murawsky, M.; Fadayel, G.M.; Fang, B.; Hare, M.; Djandjighian, L. Discovery and synthesis of tetrahydroindolone-derived carbamates as Kv1.5 blockers. Bioorg. Med. Chem. Lett. 2006, 16, 5855–5858. [Google Scholar] [CrossRef] [PubMed]
  85. Wu, S.; Fluxe, A.; Janusz, J.M.; Sheffer, J.B.; Browning, G.; Blass, B.; Cobum, K.; Hedges, R.; Murawsky, M.; Fang, B.; et al. Discovery and synthesis of tetrahydroindolone derived semicarbazones as selective Kv1.5 blockers. Bioorg. Med. Chem. Lett. 2006, 16, 5859–5863. [Google Scholar] [CrossRef] [PubMed]
  86. Nanda, K.K.; Nolt, M.B.; Cato, M.J.; Kane, S.A.; Kiss, L.; Spencer, R.H.; Wang, J.; Lynch, J.J.; Regan, C.P.; Stump, G.L.; et al. Potent antagonists of the Kv1.5 potassium channel: Synthesis and evaluation of analogous N,N-diisopropyl-2-(pyridine-3-yl)acetamides. Bioorg. Med. Chem. Lett. 2006, 16, 5897–5901. [Google Scholar] [CrossRef]
  87. Trotter, B.W.; Nanda, K.K.; Kett, N.R.; Regan, C.P.; Lynch, J.J.; Stump, G.L.; Kiss, L.; Wang, J.; Spencer, R.H.; Kane, S.A.; et al. Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation. J. Med. Chem. 2006, 49, 6954–6957. [Google Scholar] [CrossRef]
  88. Eun, J.S.; Kim, K.S.; Kim, H.N.; Park, S.A.; Ma, T.-Z.; Lee, K.A.; Kim, D.K.; Kim, H.K.; Kim, I.S.; Jung, Y.H.; et al. Synthesis of psoralen derivatives and their blocking effect of hKv1.5 channel. Arch. Pharmacol. Res. 2007, 30, 155–160. [Google Scholar] [CrossRef] [PubMed]
  89. Jackson, C.M.; Blass, B.; Coburn, K.; Djandjighian, L.; Fadayel, G.; Fluxe, A.J.; Hodson, S.J.; Janusz, J.M.; Murawsky, M.; Ridgeway, J.M.; et al. Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias. Bioorg. Med. Chem. Lett. 2007, 17, 282–284. [Google Scholar] [CrossRef] [PubMed]
  90. Lloyd, J.; Atwal, K.S.; Finlay, H.J.; Nyman, M.; Huynh, T.; Bhandaru, R.; Kover, A.; Schmidt, J.; Vaccaro, W.; Conder, M.L.; et al. Benzopyran sulfonamides as K(v)1.5 potassium channel blockers. Bioorg. Med. Chem. Lett. 2007, 17, 3271–3275. [Google Scholar] [CrossRef] [PubMed]
  91. Finlay, H.J.; Lloyd, J.; Nyman, M.; Conder, M.L.; West, T.; Levesque, P.; Atwal, K. Pyrano- [2,3b] -pyridines as potassium channel antagonists. Bioorg. Med. Chem. Lett. 2008, 18, 2714–2718. [Google Scholar] [CrossRef]
  92. Gross, M.F.; Castle, N.A.; Zou, A.; Wickenden, A.D.; Yu, W.; Spear, K.L. Aryl sulfonamido tetralin inhibitors of the Kv1.5 ion channel. Bioorg. Med. Chem. Lett. 2009, 19, 3063–3066. [Google Scholar] [CrossRef]
  93. Blass, B.E.; Fensome, A.; Trybulski, E.; Magolda, R.; Gardell, S.J.; Liu, K.; Samuel, M.; Feingold, I.; Huselton, C.; Jackson, C.M.; et al. Selective Kv1.5 blockers: Development of (R)-1-(methylsulfonylamino)-3-2-(4-methoxyphenyl)ethyl -4-(4-methoxyphe nyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia. J. Med. Chem. 2009, 52, 6531–6534. [Google Scholar] [CrossRef]
  94. Blass, B. Derivatives of heteroarylsulfonamides, their peparation, and their application in human therapy patent highlight. Acs Med. Chem. Lett. 2012, 3, 618–619. [Google Scholar] [CrossRef] [Green Version]
  95. Finlay, H.J.; Lloyd, J.; Vaccaro, W.; Kover, A.; Yan, L.; Bhave, G.; Prol, J.; Tram, H.; Bhandaru, R.; Caringal, Y.; et al. Discovery of ((S)-5-(methoxymethyl)-7-(1-methyl-1H-indol-2-yl)-2-(trifluoromethyl)-4, 7-dihydropyrazolo 1,5-a pyrimidin-6-yl)((S)-2-(3-methylisoxazol-5-yl)pyr rolidin-1-yl)methanone as a potent and selective I-Kur inhibitor. J. Med. Chem. 2012, 55, 3036–3048. [Google Scholar] [CrossRef] [PubMed]
  96. Finlay, H.J.; Jiang, J.; Caringal, Y.; Kover, A.; Conder, M.L.; Xing, D.; Levesque, P.; Harper, T.; Hsueh, M.M.; Atwal, K.; et al. Triazolo and imidazo dihydropyrazolopyrimidine potassium channel antagonists. Bioorg. Med. Chem. Lett. 2013, 23, 1743–1747. [Google Scholar] [CrossRef] [PubMed]
  97. Guo, X.; Yang, Q.; Xu, J.; Zhang, L.; Chu, H.; Yu, P.; Zhu, Y.; Wei, J.; Chen, W.; Zhang, Y.; et al. Design and bio-evaluation of indole derivatives as potent Kv1.5 inhibitors. Bioorg. Med. Chem. 2013, 21, 6466–6476. [Google Scholar] [CrossRef]
  98. Olsson, R.I.; Jacobson, I.; Bostrom, J.; Fex, T.; Bjore, A.; Olsson, C.; Sundell, J.; Gran, U.; Ohrn, A.; Nordin, A.; et al. Synthesis and evaluation of diphenylphosphinic amides and diphenylphosphine oxides as inhibitors of Kv1.5. Bioorg. Med. Chem. Lett. 2013, 23, 706–710. [Google Scholar] [CrossRef] [PubMed]
  99. Olsson, R.I.; Jacobson, I.; Iliefski, T.; Bostrom, J.; Davidsson, O.; Fjellstrom, O.; Bjore, A.; Olsson, C.; Sundell, J.; Gran, U.; et al. Lactam sulfonamides as potent inhibitors of the Kv1.5 potassium ion channel. Bioorg. Med. Chem. Lett. 2014, 24, 1269–1273. [Google Scholar] [CrossRef]
  100. Johnson, J.A.; Xu, N.; Jeon, Y.; Finlay, H.J.; Kover, A.; Conder, M.L.; Sun, H.; Li, D.; Levesque, P.; Hsueh, M.-M.; et al. Design, synthesis and evaluation of phenethylaminoheterocycles as K(v)1.5 inhibitors. Bioorg. Med. Chem. Lett. 2014, 24, 3018–3022. [Google Scholar] [CrossRef]
  101. Guo, X.; Ma, X.; Yang, Q.; Xu, J.; Huang, L.; Jia, J.; Shan, J.; Liu, L.; Chen, W.; Chu, H.; et al. Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I). Eur. J. Med. Chem. 2014, 81, 89–94. [Google Scholar] [CrossRef]
  102. Kajanus, J.; Jacobson, I.; Astrand, A.; Olsson, R.I.; Gran, U.; Bjore, A.; Fjellstrom, O.; Davidsson, O.; Emtenas, H.; Dahlen, A.; et al. Isoindolinone compounds active as Kv1.5 blockers identified using a multicomponent reaction approach. Bioorg. Med. Chem. Lett. 2016, 26, 2023–2029. [Google Scholar] [CrossRef] [PubMed]
  103. Finlay, H.J.; Johnson, J.A.; Lloyd, J.L.; Jiang, J.; Neels, J.; Gunaga, P.; Baneriee, A.; Dhondi, N.; Chimalakonda, A.; Mandlekar, S.; et al. Discovery of 5-Phenyl-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine as a Potent I-Kur Inhibitor. Acs Med. Chem. Lett. 2016, 7, 831–834. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  104. Zidar, N.; Zula, A.; Tomasic, T.; Rogers, M.; Kirby, R.W.; Tytgat, J.; Peigneur, S.; Kikelj, D.; Ilas, J.; Masic, L.P. Clathrodin, hymenidin and oroidin, and their synthetic analogues as inhibitors of the voltage-gated potassium channels. Eur. J. Med. Chem. 2017, 139, 232–241. [Google Scholar] [CrossRef] [PubMed]
  105. Wolkenberg, S.E.; Nolt, M.B.; Bilodeau, M.T.; Trotter, B.W.; Manley, P.J.; Kett, N.R.; Nanda, K.K.; Wu, Z.C.; Cato, M.J.; Kane, S.A.; et al. Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics. Bioorg. Med. Chem. Lett. 2017, 27, 1062–1069. [Google Scholar] [CrossRef] [PubMed]
  106. Kajanus, J.; Antonsson, T.; Carlsson, L.; Jurva, U.; Pettersen, A.; Sundell, J.; Inghardt, T. Potassium channel blocking 1,2-bis(aryl)ethane-1,2-diamines active as antiarrhythmic agents. Bioorg. Med. Chem. Lett. 2019, 29, 1241–1245. [Google Scholar] [CrossRef]
  107. Banerjee, S.; Adhikari, N.; Amin, S.A.; Jha, T. Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview. Eur. J. Med. Chem. 2019, 164, 214–240. [Google Scholar] [CrossRef] [PubMed]
  108. Zhao, Z.; Song, H.; Xie, J.; Liu, T.; Zhao, X.; Chen, X.; He, X.; Wu, S.; Zhang, Y.; Zheng, X. Research progress in the biological activities of 3,4,5-trimethoxycinnamic acid (TMCA) derivatives. Eur. J. Med. Chem. 2019, 173, 213–227. [Google Scholar] [CrossRef]
Biomolecules 10 00010 g001 550
Figure 1. (A) Schematic representation of the hKv1.5 α-subunit with the sequence of the S6 region listed. (B) Homologous model of Kv1.5 (Q61672) with 67.2% similarity for the Kv1.5 sequence, obtained from the SWISS-MODEL database; some of the residues are slightly different from those published in previous research. (C) Basic Local Alignment Search Tool (BLAST) result of KCNA5_HUMAN (P22460), obtained from the NCBI BLAST+ database. (D) Sequence alignment ofKCNA1_HUMAN (Q09470), KCNA3_HUMAN (P22001), KCNA2_HUMAN (P16389), and KCNA5_HUMAN (P22460), acquired from the ESPript database.
Figure 1. (A) Schematic representation of the hKv1.5 α-subunit with the sequence of the S6 region listed. (B) Homologous model of Kv1.5 (Q61672) with 67.2% similarity for the Kv1.5 sequence, obtained from the SWISS-MODEL database; some of the residues are slightly different from those published in previous research. (C) Basic Local Alignment Search Tool (BLAST) result of KCNA5_HUMAN (P22460), obtained from the NCBI BLAST+ database. (D) Sequence alignment ofKCNA1_HUMAN (Q09470), KCNA3_HUMAN (P22001), KCNA2_HUMAN (P16389), and KCNA5_HUMAN (P22460), acquired from the ESPript database.
Biomolecules 10 00010 g001
Biomolecules 10 00010 g002 550
Figure 2. (A) Pharmacophore model of vernakalant (cyan ball: hydrophobic center; yellow ball: aromatic center; green ball: hydrogen bond receptor; pink ball: hydrogen bond donor; red ball: ionizable positive center); (B) potential binding domain of vernakalant in Kv1.5 (H-bond is expressed as green dashed).
Figure 2. (A) Pharmacophore model of vernakalant (cyan ball: hydrophobic center; yellow ball: aromatic center; green ball: hydrogen bond receptor; pink ball: hydrogen bond donor; red ball: ionizable positive center); (B) potential binding domain of vernakalant in Kv1.5 (H-bond is expressed as green dashed).
Biomolecules 10 00010 g002
Biomolecules 10 00010 g003 550
Figure 3. Biphenyl derivatives.
Figure 3. Biphenyl derivatives.
Biomolecules 10 00010 g003
Biomolecules 10 00010 g004 550
Figure 4. Anthranilic amides.
Figure 4. Anthranilic amides.
Biomolecules 10 00010 g004
Biomolecules 10 00010 g005 550
Figure 5. Phenoxyalkoxypsoralen analogues.
Figure 5. Phenoxyalkoxypsoralen analogues.
Biomolecules 10 00010 g005
Biomolecules 10 00010 g006 550
Figure 6. (2-phenethyl-2H-1,2,3-triazol-4-yl)(phenyl) methanones.
Figure 6. (2-phenethyl-2H-1,2,3-triazol-4-yl)(phenyl) methanones.
Biomolecules 10 00010 g006
Biomolecules 10 00010 g007 550
Figure 7. Tetrahydroindolone-derived carbamates.
Figure 7. Tetrahydroindolone-derived carbamates.
Biomolecules 10 00010 g007
Biomolecules 10 00010 g008 550
Figure 8. Tetrahydroindolone-derived semicarbazones.
Figure 8. Tetrahydroindolone-derived semicarbazones.
Biomolecules 10 00010 g008
Biomolecules 10 00010 g009 550
Figure 9. Diisopropyl amide derivatives.
Figure 9. Diisopropyl amide derivatives.
Biomolecules 10 00010 g009
Biomolecules 10 00010 g010 550
Figure 10. Isoquinoline-3-nitriles.
Figure 10. Isoquinoline-3-nitriles.
Biomolecules 10 00010 g010
Biomolecules 10 00010 g011 550
Figure 11. Psoralen derivatives.
Figure 11. Psoralen derivatives.
Biomolecules 10 00010 g011
Biomolecules 10 00010 g012 550
Figure 12. Thiazolidine derivatives.
Figure 12. Thiazolidine derivatives.
Biomolecules 10 00010 g012
Biomolecules 10 00010 g013 550
Figure 13. Benzopyran sulfonamides.
Figure 13. Benzopyran sulfonamides.
Biomolecules 10 00010 g013
Biomolecules 10 00010 g014 550
Figure 14. Thiazolidine derivatives.
Figure 14. Thiazolidine derivatives.
Biomolecules 10 00010 g014
Biomolecules 10 00010 g015 550
Figure 15. Dihydropyrazolopyrimidine derivatives.
Figure 15. Dihydropyrazolopyrimidine derivatives.
Biomolecules 10 00010 g015
Biomolecules 10 00010 g016 550
Figure 16. Aryl sulfonamido tetralin derivatives.
Figure 16. Aryl sulfonamido tetralin derivatives.
Biomolecules 10 00010 g016
Biomolecules 10 00010 g017 550
Figure 17. Structure-activity relationship (SAR) of imidazolidinone derivatives.
Figure 17. Structure-activity relationship (SAR) of imidazolidinone derivatives.
Biomolecules 10 00010 g017
Biomolecules 10 00010 g018 550
Figure 18. SAR of pyrazolodihydropyrimidines.
Figure 18. SAR of pyrazolodihydropyrimidines.
Biomolecules 10 00010 g018
Biomolecules 10 00010 g019 550
Figure 19. SAR of heteroarylsulfonamides.
Figure 19. SAR of heteroarylsulfonamides.
Biomolecules 10 00010 g019
Biomolecules 10 00010 g020 550
Figure 20. SAR of dihydropyrazolo[1,5-a]pyrimidine derivatives.
Figure 20. SAR of dihydropyrazolo[1,5-a]pyrimidine derivatives.
Biomolecules 10 00010 g020
Biomolecules 10 00010 g021 550
Figure 21. SAR of trifluoromethylcyclohexyl triazole analogues.
Figure 21. SAR of trifluoromethylcyclohexyl triazole analogues.
Biomolecules 10 00010 g021
Biomolecules 10 00010 g022 550
Figure 22. SAR of indole derivatives.
Figure 22. SAR of indole derivatives.
Biomolecules 10 00010 g022
Biomolecules 10 00010 g023 550
Figure 23. SAR of diphenylphosphinic amides and diphenylphosphine oxides.
Figure 23. SAR of diphenylphosphinic amides and diphenylphosphine oxides.
Biomolecules 10 00010 g023
Biomolecules 10 00010 g024 550
Figure 24. SAR of lactam sulfonamides.
Figure 24. SAR of lactam sulfonamides.
Biomolecules 10 00010 g024
Biomolecules 10 00010 g025 550
Figure 25. SAR of phenethylaminoheterocycles.
Figure 25. SAR of phenethylaminoheterocycles.
Biomolecules 10 00010 g025
Biomolecules 10 00010 g026 550
Figure 26. SAR of 1-aryloxyethyl piperazine derivatives.
Figure 26. SAR of 1-aryloxyethyl piperazine derivatives.
Biomolecules 10 00010 g026
Biomolecules 10 00010 g027 550
Figure 27. SAR of isoindolinones.
Figure 27. SAR of isoindolinones.
Biomolecules 10 00010 g027
Biomolecules 10 00010 g028 550
Figure 28. SAR of phenylquinazoline derivatives.
Figure 28. SAR of phenylquinazoline derivatives.
Biomolecules 10 00010 g028
Biomolecules 10 00010 g029 550
Figure 29. SAR of phenylquinazoline sulfonamide derivatives.
Figure 29. SAR of phenylquinazoline sulfonamide derivatives.
Biomolecules 10 00010 g029
Biomolecules 10 00010 g030 550
Figure 30. SAR of oroidin derivatives.
Figure 30. SAR of oroidin derivatives.
Biomolecules 10 00010 g030
Biomolecules 10 00010 g031 550
Figure 31. SAR of oroidin MK-1832.
Figure 31. SAR of oroidin MK-1832.
Biomolecules 10 00010 g031
Biomolecules 10 00010 g032 550
Figure 32. SAR of 1,2-bis(aryl)ethane-1,2-diamines.
Figure 32. SAR of 1,2-bis(aryl)ethane-1,2-diamines.
Biomolecules 10 00010 g032
Biomolecules 10 00010 g033 550
Figure 33. SAR of aplysiatoxin derivatives.
Figure 33. SAR of aplysiatoxin derivatives.
Biomolecules 10 00010 g033
Table
Table 1. Active Kv1.5 modulators.
Table 1. Active Kv1.5 modulators.
No.NameCASStatusModelMechanismRef.
Clinical Cardiovascular Drugs
1 Biomolecules 10 00010 i00154-96-6ApprovedSmooth muscle cellsBlocking hKv1.5 current with a threshold fur activation near –45 mV.[30]
2 Biomolecules 10 00010 i002504-24-5ApprovedHEK cellsInhibiting hKv1.5 current after long-term treatment, abbreviating the prolongation of action potential duration in chronic atrial fibrillation (AF).[31]
3 Biomolecules 10 00010 i003794466-70-9Approved, investigationalHEK cellsSelective blocking of the Kv1.5 channel by interacting with important residues including Thr 479, Thr 480, Ile 502, Val 505, and Val 508.[32]
4 Biomolecules 10 00010 i0041951-25-3Approved, investigationalPapillary muscles or single ventricular cellsDecreasing the amount of mRNA for Kv1.5.[33]
5 Biomolecules 10 00010 i00554143-55-4Approved, withdrawnXenopus laevis oocytesProducing open-channel block of Kv1.5 by sensitively interacting with key residues including Asp 469, Val 481, and Ile 502 in the S6 region of Kv1.5.[34]
6 Biomolecules 10 00010 i00621829-25-4ApprovedHEK cellsBlocking hKv1.5 channels with 6.3 μM of Kd was affected by mutations like Arg 487 similar to those known to affect outer pore C-type inactivation.[35]
7 Biomolecules 10 00010 i00754063-53-5ApprovedLtk- cellsInhibiting hKv1.5 current with Kdvalue of 9.2 μM, showing time-dependent and dose-dependent manners simultaneously.[36]
8 Biomolecules 10 00010 i00886384-10-3-Ltk- cellsInhibiting hKv1.5 current with Kdvalue of 4.4 μM, showing time-dependent and dose-dependent manners simultaneously.[36]
9 Biomolecules 10 00010 i00956-54-2Approved, investigationalHEK cellsProducing a voltage-dependent block between +30 and +120 mV (Kd at +60 mV = 7.2 μM) with an equivalent electrical distance in the steady state.[37]
10 Biomolecules 10 00010 i01042399-41-7Approved, investigationalCHO cellsBlocking hKv1.5 channels, in a frequency-dependent manner exhibiting a biphasic dose-response curve (IC50: 4.8 nM and 42.3 μM) by binding to the open and inactivated state of the channels.[38]
11 Biomolecules 10 00010 i01166-40-0Experimental, investigationalBT-474 breast cancer cellBlocking hKv1.5 channels in a delayed rectifier manner.[39]
12 Biomolecules 10 00010 i01268379-03-3-CHO cellsInhibiting hKv1.5 current with concentration-dependent acceleration of the apparent channel inactivation in both outside-out and inside-out patches.[40]
13 Biomolecules 10 00010 i013163163-23-3-CHO cellsBlocking hKv1.5 current stereoselectivity, the results showed that (-)-[3R, 4S] was more potent than the (-)-enantiomer.[41]
14 Biomolecules 10 00010 i01464706-54-3Approved, withdrawnHEK cellsInhibiting the hKv1.5 channel current with IC50 value of 6.6 μM.[42]
Other Clinical Drugs
15 Biomolecules 10 00010 i015120014-06-4ApprovedHEK cellsResulting in a rapid and reversible block of Kv1.5 currents (IC50: 72.5 μM) with a significant delay in the duration of activation and deactivation, and the outer mouth region proved to be the target site.[15]
16 Biomolecules 10 00010 i01661869-08-7Approved, investigationalCHO cellsSlowing the deactivation time course, resulting in a tail crossover phenomenon when the tail currents, recorded in the presence and absence of paroxetine, were superimposed.[43]
17 Biomolecules 10 00010 i01754910-89-3Approved, vet approvedHuman Pulmonary Artery Smooth Muscle CellsProtecting against big endothelin-1 induced anti-apoptosis and rescued Kv1.5 channels in human pulmonary arterial smooth muscle cells.[44]
18 Biomolecules 10 00010 i01879617-96-2ApprovedCHO cellsReducing Kv1.5 whole-cell currents in a reversible dose-dependent manner and accelerating the decay rate of inactivation of Kv1.5 currents without modifying the kinetics of current activation.[45]
19 Biomolecules 10 00010 i01953-06-5ApprovedXenopus oocytesSuppressing the amplitude of Kv1.5 channel current with IC50 value of 50.2 μM.[46]
20 Biomolecules 10 00010 i02050-23-7Approved, vet approvedXenopus oocytesSuppressing the amplitude of Kv1.5 channel current with IC50 value of 33.4 μM.[46]
21 Biomolecules 10 00010 i02152-01-7ApprovedMale Wistar ratsShorting the APD90(action potential duration) and increasing the expression of Kv1.5.[47]
22 Biomolecules 10 00010 i022169590-42-5Approved, investigationalLtk- cellsBlocking hKv1.5 channels with an IC50 of 26.2 μM for the peak current and 5.5 μM for the current at the end of a 250 ms pulse to +60 mV.[48]
23 Biomolecules 10 00010 i02338396-39-3Approved, investigationalLtk- cellsBlocking the opening of hKv1.5 channels stereoselectivity; the results showed the Kd value for R(+)-enantiomer (4.1 μM) was six-fold more potent than the S(-)-enantiomer (27.3 μM).[49,50]
24 Biomolecules 10 00010 i0242078-54-8Approved, investigational, vet approvedCHO cellsInducing a time-dependent decline of the hKv1.5 current (IC50: 62.9 μM) during depolarizing steps and slowing the time course of tail current decay upon repolarization.[4]
25 Biomolecules 10 00010 i02559467-70-8ApprovedHEK cellsInhibited Kv1.5 current (IC50: 17 μM) without influence on the half-maximal activation voltage of Kv1.5 channels.[51]
26 Biomolecules 10 00010 i02664-77-7Approved, investigationalInsulin-secreting (INS-1) cellsActivating Kv1.5 channel and the activation of secretion can be counteracted by an excessive stimulation of Kv channels in INS-1 cells which shorten the Ca2+ signal and confine the insulin secretion.[52]
27 Biomolecules 10 00010 i02794-09-7ApprovedLtk- cellsBlocking hKv1.5 channels in a voltage-dependent manner and modifying the voltage-dependence of channel activation.[53]
Drugs in Development
28 Biomolecules 10 00010 i0281163-36-6Phase 2 ClinicalHEK cellsDecreasing IKs and human Kv1.5 channel current at doses of 3 and 10 μM at voltages ranging from –14.3 to +34.7 mV.[54]
29 Biomolecules 10 00010 i029767334-89-4Phase 1 discontinuedCHO cellsInhibiting hKv1.5 current with IC50 value of 3.6 μM, blocking early atrial K+ channels, and prolonging atrial refractoriness with no effects on electrocardiography intervals and ventricular repolarization.[55]
30 Biomolecules 10 00010 i030864368-79-6Phase 2 discontinuedCHO cellsBlocking hKv1.5 current with IC50 value of 27 μM with a slight decrease at higher frequency.[56]
31 Biomolecules 10 00010 i031343246-73-1Phase 1 discontinuedMouse fibroblast L929 cellsShowing excellent activity in blocking Kv1.5 (IC50: 0.05 μM) and very good selectivity over hERG, sodium, and L-type calcium ion channels.[57]
32 Biomolecules 10 00010 i0321272353-82-8Phase 1 discontinuedMammalian L-929 cellsBlocking hKv1.5 current with IC50 value of 0.05 μM with an acceptable in vitroselectivity and liability profile and a good pharmacokinetic profile across species.[58]
33 Biomolecules 10 00010 i033875562-81-5Phase 1 discontinuedHK2BN9 cellsBlocking Kv1.5 current in an expression system and concentration-dependently elevated the plateau phase of atrial action potentials (APs).[59]
34XEN-D0103
(Undisclosed structure)		1410180-16-3Phase 2 discontinuedCHO cellsProlongating action potential duration (APD) and suppressed APs at high stimulation rates in sinus rhythm (SR) and paroxysmal AF (pAF) tissue.[60]
35 Biomolecules 10 00010 i034154447-36-6ExperimentalCHO cellsActing directly on hKv1.5 currents as an open channel blocker with key interacting residues located in the pore region (Thr 480, Arg 487) and the S6 segment (Ile 502, Ile 508, Leu 510, Val 516).[9]
36 Biomolecules 10 00010 i035752253-75-1-CHO cellsInhibiting several potassium currents including IKr, IKs, IK(ACh), and IKv1.5 at doses of 0.01–30 μM.[61]
37 Biomolecules 10 00010 i0361034194-07-4-HEK cellsInhibiting hKv1.5 current slightly when specially blocked by the Kv11.1 channel.[62]
Natural ProductsType
38 Biomolecules 10 00010 i0372334247-91-3TerpenoidCHO cellsBlocking Kv1.5 with an IC50 value of 6.94 μM.[63]
39 Biomolecules 10 00010 i0382334247-94-6TerpenoidCHO cellsBlocking Kv1.5 with an IC50 value of 0.30 μM.[63]
40 Biomolecules 10 00010 i03957444-62-9TerpenoidC6 glioma cellsInhibiting the hKv1.5 current in time and dose-dependent manners.[64]
41 Biomolecules 10 00010 i04013018-10-5TerpenoidLtk- cellsInhibiting the hKv1.5 current in time- and voltage-dependent manners, with an IC50 value of 2.51 μM at +60 mV accelerated the inactivation kinetics of the hKv1.5 channel and slowed the deactivation kinetics of the hKv1.5 current, resulting in a tail crossover phenomenon.[65]
42 Biomolecules 10 00010 i0411394-48-5AlkaloidGuinea pigsBlocking I-Kv1.5 slightly with a ratio of 20.6% at a dosage of 200 μM.[66]
43 Biomolecules 10 00010 i04290-69-7AlkaloidHEK cellsAccelerating the decay rate of Kv1.5 inactivation, decreased the current amplitude at the end of the pulse in a concentration-dependent manner with an IC50 value of 15.1 μM.[67]
44 Biomolecules 10 00010 i0434360-12-7AlkaloidXenopus oocytesInhibiting Kv1.5 with an IC50 of 1.70 μM in Xenopus expression system, resulting in a mild leftward shift of Kv1.5 activation curve.[68]
45 Biomolecules 10 00010 i04458-74-2AlkaloidLtk- cellsBlocking hKv1.5 channels and native hKv1.5 channels in a concentration-, voltage-, state-, and time-dependent manner.[69]
46 Biomolecules 10 00010 i0452934-97-6AlkaloidHEK cellsBlocking Kv1.5 currents dose-dependently with an IC50 value of 53.2 μM inhibited the delayed rectifier effect of Kv1.5 resulting in a potential left shift of the inactivation curve.[70]
47 Biomolecules 10 00010 i046302-27-2AlkaloidXenopus laevis oocytesProducing a voltage-, time-, and frequency-dependent inhibition of Kv1.5 (IC50: 0.796 μM).[71]
48 Biomolecules 10 00010 i047529-44-2FlavonoidHEK cellsInhibiting Ikur and the expression of hKv1.5 in a dose-, time-, and frequency-dependent manner.[72]
49 Biomolecules 10 00010 i0485631-70-9FlavonoidHEK cellsSuppressing hKv1.5 current in HEK 293 cell line (IC50: 6.4 μM) and the ultra-rapid delayed rectify K+ current IKur in human atrial myocytes (IC50: 8.0 μM) by binding to open channels in a use- and frequency-dependent manner.[73]
50 Biomolecules 10 00010 i049117-39-5FlavonoidXenopus laevisoocytesActivating hKv1.5 channels (EC50: 37.8 μM) by interacting with key residue Ile 502 in S6 region.[74]
51 Biomolecules 10 00010 i050480-44-4FlavonoidHEK cellsBlocking open hKv1.5 channels by binding to their S6 domain influenced by the interaction of V505A, I508A, and V512A.[75]
52 Biomolecules 10 00010 i051501-36-0PhenolHuman PASMCsReducing the expression of Kv1.5 mRNA to reverse monocrotaline-induced pulmonary vascular and cardiac dysfunction.[76]
53 Biomolecules 10 00010 i0525928-25-6CoumarinLtk− cellsInhibiting hKv1.5 current in a concentration- and use-dependent manner, with an IC50 value of 2.7 μM at +60 mV accelerated the inactivation kinetics of the hKv1.5 channel, resulting in a tail crossover phenomenon.[77]
54Kaliotoxin145199-73-1PolypeptideT cellInhibiting hKv1.5 current in a dose-dependent manner.[64]
55 Biomolecules 10 00010 i053190017-00-6Nor-triterpenoidCHO cellsInhibiting Kv1.5 with an IC50 of 1.77 μM and influenced by the mutations T480A, V505A, I508A, as well as V516A.[78]
56 Biomolecules 10 00010 i054107-35-7Amino acidMale Wistar ratsDown-regulating the mRNA expression level of Kv1.5.[79]

Share and Cite

MDPI and ACS Style

Zhao, Z.; Ruan, S.; Ma, X.; Feng, Q.; Xie, Z.; Nie, Z.; Fan, P.; Qian, M.; He, X.; Wu, S.; et al. Challenges Faced with Small Molecular Modulators of Potassium Current Channel Isoform Kv1.5. Biomolecules 2020, 10, 10. https://doi.org/10.3390/biom10010010

AMA Style

Zhao Z, Ruan S, Ma X, Feng Q, Xie Z, Nie Z, Fan P, Qian M, He X, Wu S, et al. Challenges Faced with Small Molecular Modulators of Potassium Current Channel Isoform Kv1.5. Biomolecules. 2020; 10(1):10. https://doi.org/10.3390/biom10010010

Chicago/Turabian Style

Zhao, Zefeng, Songsong Ruan, Xiaoming Ma, Qian Feng, Zhuosong Xie, Zhuang Nie, Peinan Fan, Mingcheng Qian, Xirui He, Shaoping Wu, and et al. 2020. "Challenges Faced with Small Molecular Modulators of Potassium Current Channel Isoform Kv1.5" Biomolecules 10, no. 1: 10. https://doi.org/10.3390/biom10010010

APA Style

Zhao, Z., Ruan, S., Ma, X., Feng, Q., Xie, Z., Nie, Z., Fan, P., Qian, M., He, X., Wu, S., Zhang, Y., & Zheng, X. (2020). Challenges Faced with Small Molecular Modulators of Potassium Current Channel Isoform Kv1.5. Biomolecules, 10(1), 10. https://doi.org/10.3390/biom10010010

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop